Meta-analysis: The efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Han, Tianzhao ^a   Rong, Gong ^a   Quan, Dayong ^a   Shu, Ying ^a   Liang, Zhu ^a   She, Ninglan ^a   Liu, Manli ^a   Yang, Bing ^a   Cheng, Gong ^a   Lv, Yongman ^b   Stern, Leonard ^c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; PARICALCITOL; PLACEBO; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ERGOCALCIFEROL; VITAMIN D;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; META ANALYSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; RISK; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; ERGOCALCIFEROLS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME; VITAMIN D;

EID: 84874612437     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/320560     Document Type: Article

References (46)

1. Mizobuchi M., Aoshima Y., Akizawa T., CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder. Clinical Calcium 2010 20 7 995 1003 2-s2.0-77957672352
2. Suchowierska E., Myśliwiec M., Chronic kidney disease related to mineral and bone disorders. Polski Merkuriusz Lekarski 2010 28 164 138 143 2-s2.0-77949468099
3. Komaba H., CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD. Clinical Calcium 2010 20 7 1028 1036 2-s2.0-77957680094
4. Fishbane S., Chittineni H., Packman M., Dutka P., Ali N., Durie N., Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. American Journal of Kidney Diseases 2009 54 4 647 652 2-s2.0-70349251198 10.1053/j.ajkd.2009.04.036
5. Alborzi P., Patel N. A., Peterson C., Bills J. E., Bekele D. M., Bunaye Z., Light R. P., Agarwal R., Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial. Hypertension 2008 52 2 249 255 2-s2.0-49849104171 10.1161/HYPERTENSIONAHA.108.113159
6. Agarwal R., Acharya M., Tian J., Hippensteel R. L., Melnick J. Z., Qiu P., Williams L., Batlle D., Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International 2005 68 6 2823 2828 2-s2.0-32844466369 10.1111/j.1523-1755.2005.00755.x (Pubitemid 43251029)
7. Martin K. J., González E. A., Gellens M., Hamm L. L., Abboud H., Lindberg J., 19-nor-1- α -25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Journal of the American Society of Nephrology 1998 9 8 1427 1432 2-s2.0-0345403572 (Pubitemid 28354552)
8. Abboud H., Coyne D., Smolenski O., Anger M., Lunde N., Qiu P., Hippensteel R., Pradhan R. S., Palaparthy R. V., Kavanaugh A., Melnick J. Z., Williams L. A., Batlle D., A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. American Journal of Nephrology 2006 26 1 105 114 2-s2.0-33645699069 10.1159/000092033
9. Coyne D., Acharya M., Qiu P., Abboud H., Batlle D., Rosansky S., Fadem S., Levine B., Williams L., Andress D. L., Sprague S. M., Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. American Journal of Kidney Diseases 2006 47 2 263 276 2-s2.0-31044455712 10.1053/j.ajkd.2005.10.007 (Pubitemid 43121329)
10. Greenbaum L. A., Benador N., Goldstein S. L., Paredes A., Melnick J. Z., Mattingly S., Amdahl M., Williams L. A., Salusky I. B., Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. American Journal of Kidney Diseases 2007 49 6 814 823 2-s2.0-34249081159 10.1053/j.ajkd.2007.03.008 (Pubitemid 46802931)
11. Ross E. A., Tian J., Abboud H., Hippensteel R., Melnick J. Z., Pradhan R. S., Williams L. A., Hamm L. L., Sprague S. M., Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. American Journal of Nephrology 2007 28 1 97 106 2-s2.0-36248961169 10.1159/000109398
12. De Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., Parving H. H., Pritchett Y., Remuzzi G., Ritz E., Andress D., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet 2010 376 9752 1543 1551 2-s2.0-78149359262 10.1016/S0140-6736(10)61032-X
13. Szeto C. C., Chow K. M., Kwan B. C. H., Chung K. Y., Leung C. B., Li P. K. T., Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin a nephropathy: an uncontrolled trial. American Journal of Kidney Diseases 2008 51 5 724 731 2-s2.0-43049104680 10.1053/j.ajkd.2007.12.038 (Pubitemid 351626254)
14. Cheng J., Zhang W., Zhang X., Li X., Chen J., Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clinical Journal of the American Society of Nephrology 2012 7 3 391 400 10.2215/CJN.03000311
15. 3 users in a haemodialysis population. Nephrology Dialysis Transplantation 2004 19 1 179 184 2-s2.0-9144265456 10.1093/ndt/gfg513 (Pubitemid 38072630)
16. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J. M., Thadhani R., Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New England Journal of Medicine 2003 349 5 446 456 2-s2.0-0042343804 10.1056/NEJMoa022536 (Pubitemid 36910023)
17. Tentori F., Hunt W. C., Stidley C. A., Rohrscheib M. R., Bedrick E. J., Meyer K. B., Johnson H. K., Zager P. G., Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney International 2006 70 10 1858 1865 2-s2.0-33750576187 10.1038/sj.ki.5001868 (Pubitemid 44684819)
18. Mathew S., Lund R. J., Chaudhary L. R., Geurs T., Hruska K. A., Vitamin D receptor activators can protect against vascular calcification. Journal of the American Society of Nephrology 2008 19 8 1509 1519 2-s2.0-49649088934 10.1681/ASN.2007080902
19. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J. M., Gavaghan D. J., McQuay H. J., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 17 1 1 12 2-s2.0-0029914622 10.1016/0197-2456(95)00134-4 (Pubitemid 26120810)
20. Higgins J. P., Green S., Cochrane Handbook for Systematic Reviews of Interventions 2008 Cochrane Collaboration
21. Higgins J. P. T., Thompson S. G., Deeks J. J., Altman D. G., Measuring inconsistency in meta-analyses. British Medical Journal 2003 327 7414 557 560 2-s2.0-0041876133 (Pubitemid 37088507)
22. Higgins J. P. T., Thompson S. G., Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002 21 11 1539 1558 2-s2.0-0037098199 10.1002/sim.1186 (Pubitemid 34746062)
23. Lambers Heerspink H. J., Agarwal R., Coyne D. W., Parving H. H., Ritz E., Remuzzi G., Audhya P., Amdahl M. J., Andress D. L., De Zeeuw D., The selective vitamin d receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. American Journal of Nephrology 2009 30 3 280 286 2-s2.0-66749092987 10.1159/000225903
24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International, Supplement 2009 76 113 S1 S130
25. Cozzolino M., Missaglia E., Ortiz A., Bellasi A., Adragao T., Apostolou T., Vescovo G., Gallieni M., Vascular calcification in chronic kidney disease. Recenti Progressi in Medicina 2010 101 11 442 452 2-s2.0-78751629718 10.1701/526.6287
26. Joki N., Tanaka Y., CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients. Clinical Calcium 2010 20 7 1061 1066 2-s2.0-77957660193
27. Bover J., Aguilar A., Baas J. P., Reyes J., Lloret M. J., Farré N., Olaya M., Canal C., Marco H., Andrés E., Trinidad P., Ballarín J., Calcimimetics in the chronic kidney disease-mineral and bone disorder. International Journal of Artificial Organs 2009 32 2 108 121 2-s2.0-67649304664
28. Goodman W. G., Recent developments in the management of secondary hyperparathyroidism. Kidney International 2001 59 3 1187 1201 2-s2.0-0035092352 10.1046/j.1523-1755.2001.0590031187.x (Pubitemid 32206887)
29. Slatopolsky E., Weerts C., Thielen J., Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25- dihydroxycholecalciferol in uremic patients. Journal of Clinical Investigation 1984 74 6 2136 2143 2-s2.0-0021748474 (Pubitemid 15197358)
30. 3 on intestinal calcium and phosphate transport. Journal of Laboratory and Clinical Medicine 2002 139 5 279 284 2-s2.0-0036014829 10.1067/mlc.2002.122819 (Pubitemid 34577479)
31. Lund R. J., Andress D. L., Amdahl M., Williams L. A., Heaney R. P., Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. American Journal of Nephrology 2010 31 2 165 170 2-s2.0-72049092449 10.1159/000266204
32. Silver J., Russell J., Sherwood L. M., Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proceedings of the National Academy of Sciences of the United States of America 1985 82 12 4270 4273 2-s2.0-0006519608 (Pubitemid 15053625)
33. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986 119 6 2864 2866 2-s2.0-0023034788 (Pubitemid 17193160)
34. Silver J., Naveh-Many T., Mayer H., Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. Journal of Clinical Investigation 1986 78 5 1296 1301 2-s2.0-0022971152 (Pubitemid 17181568)
35. 3 Journal of Biological Chemistry 1988 263 5 2203 2208 2-s2.0-0023851754 (Pubitemid 18060274)
36. Gupta D., Brietzke S., Hayden M. R., Kurukulasuriya L. R., Sowers J. R., Phosphate metabolism in cardiorenal metabolic disease. Cardiorenal Medicine 2011 1 4 261 270 10.1159/000332388
37. Kendrick J., Chonchol M., The role of phosphorus in the development and progression of vascular calcification. American Journal of Kidney Diseases 2011 58 5 826 834 10.1053/j.ajkd.2011.07.020
38. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J. M., Thadhani R., Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New England Journal of Medicine 2003 349 5 446 456 2-s2.0-0042343804 10.1056/NEJMoa022536 (Pubitemid 36910023)
39. 3 on serum calcium and phosphorus in hemodialysis patients. American Journal of Kidney Diseases 2002 40 6 1283 1288 2-s2.0-0036895239 10.1053/ajkd.2002.36899 (Pubitemid 35403141)
40. National Kidney Foundation, KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases 2003 42 supplement 3 S1 S201
41. 3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. Journal of Clinical Endocrinology and Metabolism 1983 57 6 1308 1310 2-s2.0-0021089040 (Pubitemid 14209439)
42. 3 is a potent suppressor of interferon γ -mediated macrophage activation. Blood 2005 106 13 4351 4358 2-s2.0-28844438923 10.1182/blood-2005- 03-1029 (Pubitemid 41775947)
43. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. Journal of Immunology 2000 164 5 2405 2411 2-s2.0-0034161714 (Pubitemid 30115468)
44. 3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation 2002 110 2 229 238 2-s2.0-0036073755 10.1172/JCI200215219 (Pubitemid 34787360)
45. Zhang Z., Zhang Y., Ning G., Deb D. K., Kong J., Yan C. L., Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proceedings of the National Academy of Sciences of the United States of America 2008 105 41 15896 15901 2-s2.0-57349185929 10.1073/pnas.0803751105
46. Slatopolsky E., Brown A., Dusso A., Pathogenesis of secondary hyperparathyroidism. Kidney International, Supplement 1999 56 S14 S19 2-s2.0-0033395674 (Pubitemid 30012822)